SCHEMBL2839406

SCHEMBL2839406

OCc1cc(Nc2ccccc2)n(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.60
HPGD P15428 3/20 0.60
MAPK1 P28482 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.50
GFER P55789 1/20 0.50
MAPT P10636 1/20 0.50
RECQL P46063 1/20 0.50
ALDH1A1 P00352 3/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
KCNJ6 P48051 5/20 0.43
KCNJ5 P48544 5/20 0.43
KCNJ3 P48549 5/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
PTGS2 P35354 1/20 0.42
P2RX7 Q99572 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2841874 0.88 GAA (0.49) GAAHPGDMAPK1SMN1; SMN2GFER
Hydrochloric Acid SCHEMBL2839560 0.81 GAA (0.60) GAAHPGDMAPK1SMN1; SMN2GFER
SCHEMBL16780330 0.80 ALDH1A1 (0.59) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL2840465 0.78 GAA (0.53) GAAHPGDMAPK1SMN1; SMN2GFER
SCHEMBL28210277 0.78 ALDH1A1 (0.50) GAASMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL2837900 0.77 GAA (0.67) GAAALDH1A1LMNA
SCHEMBL2837826 0.76 ALDH1A1 (0.57) ALDH1A1LMNATSHRNPSR1CA1
SCHEMBL11535423 0.76 GAA (1.00) GAAHPGDMAPK1SMN1; SMN2GFER
SCHEMBL13858692 0.74 FAAH (0.51) GAAMAPTALDH1A1LMNAKCNJ6
SCHEMBL16804455 0.73 MAPT (0.63) GAAMAPK1MAPTALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162798-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2017-05-03 EP disclosed
EP-2196459-B1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL (JP) 2016-11-02 EP disclosed
US-8334301-B2 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-18 US disclosed
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-19 US disclosed
EP-2196459-A1 5-MEMBERED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210696-A1 5-MEMBERED HETEROCYCLIC COMPOUND NPY4R, NPY5R, NPY1R GAA 1513/4885HPGD 138/4885MAPK1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.